SAB Biotherapeutics, Inc. ( NASDAQ:SABS – Get Rating ) – HC Wainwright boosted their Q2 2023 earnings per share (EPS) estimates for SAB Biotherapeutics in a research note issued on Wednesday, May 17th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($0.16) per share for the quarter, up from their prior estimate of ($0.19). HC Wainwright currently has a 'Buy' rating and a $4.00 target price on the stock. The consensus estimate for SAB Biotherapeutics' current full-year earnings is ($0.

https://www.dailypolitical.com/2023/05/20/sab-biotherapeutics-inc-to-post-q2-2023-earnings-of-0-16-per-share-hc-wainwright-forecasts-nasdaqsabs.html

#dailypolitical